Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D P Berger

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Clinical Pharmacology and Therapeutics|February 14, 2015
Improving evidence developed from population-level experience with targeted agentsM B McClellan, G W Daniel, D Dickson, et al.
Journal of Medical Genetics|August 3, 2001
VHL c.505 T>C mutation confers a high age related penetrance but no increased overall mortalityB U Bender, C Eng, M Olschewski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1992
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agentH R Hendriks, J Plowman, D P Berger, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical modelsH R Hendriks, P E Pizao, D P Berger, et al.
The Journal of Urology|September 29, 1998
Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinomaH P Neumann, B U Bender, D P Berger, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Clinical Pharmacology and Therapeutics|February 14, 2015
Improving evidence developed from population-level experience with targeted agentsM B McClellan, G W Daniel, D Dickson, et al.
Journal of Medical Genetics|August 3, 2001
VHL c.505 T>C mutation confers a high age related penetrance but no increased overall mortalityB U Bender, C Eng, M Olschewski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1992
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agentH R Hendriks, J Plowman, D P Berger, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical modelsH R Hendriks, P E Pizao, D P Berger, et al.
The Journal of Urology|September 29, 1998
Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinomaH P Neumann, B U Bender, D P Berger, et al.
Pageof 4